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INTRODUCTION
Acute myeloid leukemia (AML) is a genetically heterogeneous disease with poor long-term survival of the majority of patients undergoing current chemotherapies. The identification of leukemiaspecific antigens and recent clinical advances in cancer immunotherapy underscore the potential for safer and more effective AML treatments 1, 2 . However, adoptive T cell transfer and vaccination strategies were so far hampered by the immunosuppressive tumor microenvironment. The immune tolerance in AML results from the accumulation of immature dendritic cells (DC), myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) associated with high expression of Th2 cytokines (IL-4, IL-6, IL-10), TGFβ, or coinhibitory molecules, such as PD-L1 [3] [4] [5] . In addition, the myeloid cell-specific antigen-presentation and expression of proinflammatory cytokines/chemokines, such as IL-12, are downregulated in leukemia 4, 6 .
Similar to other blood cancers, AML patients show high frequency of STAT3 activation in leukemic blasts which correlates with decreased disease-free survival [7] [8] [9] . STAT3 is plays a role in promoting AML cell proliferation and survival but whether it contributes to immune evasion was not clearly demonstrated 7, 10, 11 . Earlier studies indicated that STAT3 activation is also common in many tumor-associated myeloid cell populations, which contribute to tumorigenesis 12 . It is an attractive but challenging target for cancer therapy, as pharmacologic inhibition of non-enzymatic protein proved difficult 8, 12 .Targeting tyrosine kinases upstream from STAT3 using small molecule inhibitors of JAK, SRC, c-KIT and FLT3 provided an alternative strategy for AML therapy but therapeutic effects in most clinical trials were short-lived 8, 13 .
Growing evidence suggest that to generate long-lasting effects cancer immunotherapies need to alleviate tumor tolerance before jump-starting antitumor immune responses 2, 14 . We have previously
shown that STAT3 activity in tumor-associated myeloid cells hampered the effect of locally administered CpG-oligodeoxyribonucleotide (ODN), a TLR9 ligand and clinically-relevant immunoadjuvant 15 . These results provided a possible explanation for limited clinical efficacy of TLR9 agonists against human cancers, including AML 16, 17 . We later demonstrated that CpG-ODNs can be utilized for cell-specific siRNA delivery, as CpG-siRNA conjugate, to silence genes in mouse and
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In vivo experiments
C57BL/6 and NOD/SCID/IL-2RγKO (NSG) mice (6-8 weeks old) were from the NCI (Frederick, MD) or from the Jackson Laboratory, respectively. TLR9KO mice were originally from S. Akira (Osaka University, Japan). Animal care/procedures were performed in accordance with established institutional guidance and approved protocols from the IACUC (COH). C57BL/6 mice were injected into lateral tail vein with 1×10 6 of Cbfb-MYH11/Mpl + AML cells in PBS. For CD8 + T cell depletion, mice were injected i.p. with anti-CD8 antibody (200 μg) on day -6, -3 and 0 before tumor challenge and then twice weekly. Blood was drawn from the retro-orbital venous sinus to monitor the circulating cKit + /GFP + AML cells. After AML levels in blood exceeded 1% which corresponds to 10-20% of bone marrow-residing AML cells (Kuo, unpublished) , mice were injected i.v. 6 times with various CpGsiRNAs (5mg/kg) every other day and euthanized a day after the last treatment.
Flow cytometry and immunohistochemistry
Single cell suspensions were prepared by mechanic tissue disruption and collagenase-D/DNase-I treatment as described 24 . The AML cell percentages were determined by GFP and c-Kit expression.
For extracellular staining, cells were incubated with fluorochrome-labeled antibodies to MHC class II,
For personal use only. on September 24, 2017 . by guest www.bloodjournal.org From CD40, CD80, CD86, PDL1, CD3, CD4, CD8, CD69 and anti-FcγIII/IIR blocking (eBioscience). For intracellular staining, cells were fixed/permeabilized and stained with TLR9-specific antibodies (eBioscience), Stat3P or FoxP3 (BD) as described 18 . Fluorescence data were analyzed on BDAccuriC6 Flow Cytometer (BD) using FlowJo software (TreeStar). Immunohistochemical staining was performed on formalin-fixed/paraffin-embedded bone sections (5 μm) at the Pathology Core (COH).
Quantitative real-time PCR and protein assays
Total RNA isolation and cDNA synthesis were carried out as described previously 20 . The sequences of the specific primers/probe sets are listed in the Supplementary Materials. Western blot to detect Stat3, Stat3P and β -actin expression was performed as described 24 . Plasma cytokines were analyzed using Bio-Plex arrays (Bio-Rad) at the Clinical Immunobiology Core (COH). 
IFNγ ELISPOT assay

Statistical analysis
One-or two-way ANOVA plus Bonferroni post-test were applied to assess statistical significance of differences between multiple treatment groups or in tumor growth kinetics between treatment groups, respectively. Data were analyzed using GraphPad Prism vs4.0 software (GraphPad). (Fig. 1C, left) . The conjugate uptake increased with longer incubation and peaked at 4 h. The maximum cell internalization required 250-500 nM concentrations (Fig. 1C,   middle ). In contrast, the unconjugated Stat3 siRNA was not significantly internalized even after 4 h incubation at 500 nM concentration (Fig. 1C, right) . The rapid uptake limits exposure of the naked oligonucleotide to serum nucleases in the environment. Thus, we assessed the potential of using reduced AML burden in donor mice (Fig. 2) , it did not reduce leukemia-initiating potential in secondary recipients (Fig. 3A) . These results prompted us to evaluate effect of prolonged STAT3-inhibition/TLR9-activation. The repeated CpG-Stat3 siRNA administration twice weekly for over 7
weeks resulted in survival of 60% of mice while no mice survived in CpG-Luciferase siRNA-treated and untreated groups (Fig. 3C ). Long term administration of CpG-Stat3 siRNA did not cause obvious adverse effects and/or immunotoxicity. Together, these data demonstrate that targeted STAT3-inhibition/TLR9-activation effectively impairs leukemia-initiating potential of CMM + AML, thereby preventing tumor recurrence.
Anti-leukemic effects of CpG-Stat3 siRNA depend on intact immune system
We previously demonstrated that targeting STAT3 using CpG-siRNA can induce direct cytotoxic effects against human TLR9-positive hematologic malignancies in immunodeficient mice 20 . To verify whether intact immune system is required for antitumor effect of CpG-Stat3 siRNA against CMM + AML, we engrafted leukemic cells into immunodeficient NSG mice. Mice with established tumors (day 7), were treated using 6 repeated i.v. injections of CpG-siRNAs as in Figure 2 . Although, CpG-Stat3 siRNA significantly downregulated Stat3 expression in AML cells (Fig. 4A) , it failed to restrain leukemia progression in NSG mice (Fig. 4B) . These results indicate that direct cytotoxic effect of STAT3-inhibition/TLR9-activation on CMM + AML cells in vivo is negligible, corresponding to weak CpG-Stat3 siRNA cytotoxicity to leukemic cell in vitro ( Supplementary Fig. 4 
Targeted STAT3-inhibition/TLR9-activation augments immunogenicity of AML cells in vivo
Earlier studies demonstrated that proinflammatory cytokines can induce in vitro differentiation and antigen-presenting functions of AML cells 29, 30 . Therefore, we analyzed surface expression of antigenpresenting molecules on in vivo-treated leukemic cells. Wild-type mice with established CMM + AML were injected using CpG-Stat3 siRNA, CpG-Luciferase siRNA or left untreated (as described in Fig.   4A ). CpG-Stat3 siRNA treatment induced upregulation of MHC class II, CD40, CD80 and CD86 molecules on splenic GFP + AML cells, while the immunostimulatory effect of CpG-Luciferase siRNA was insignificant (Fig. 5A ). The levels of immunostimulatory molecules induced by STAT3 targeting were comparable between AML cells (GFP + ) and normal DCs (GFP -) isolated from lymph nodes of the same mice ( Supplementary Fig. 5A ). In contrast, levels of a coinhibitory PD-L1 molecule, implicated in tumor immune tolerance, were significantly reduced in AML cells after Stat3 silencing (Fig. 5B ) 31 . We also found that mice from CpG-Stat3 siRNA-treated group but not control animals had highly elevated plasma levels of proinflammatory mediators, such as IFNγ, IL-12 and CXCL9/MIG ( Fig. 5C ) with concomitant reduction of Th2 cytokines, such as IL-4 and IL-6 (Fig. 5D) . Finally, we evaluated whether the CpG-Stat3 siRNA-treated AML cells are capable of T cell activation. In vitro coculture of AML cells freshly isolated from CpG-siRNA-treated mice, with CD3 + T cells isolated from naïve mice, demonstrated the superior potential of CpG-Stat3 siRNA to induce AML-dependent T cell proliferation compared to CpG-Luciferase siRNA-treated or untreated mice (Fig. 5E ).
CpG-Stat3 siRNA increases the ratio of CD8 + effector to regulatory T cells in vivo
Next, we investigated whether increased AML immunogenicity in CpG-Stat3 siRNA-treated mice will induce CD8 + T cell infiltration into major leukemia reservoirs such as bone marrow and spleen. As shown in Figure 6A , the average percentage of CD8 + T cells in spleen and bone marrow increased ~5-fold in AML-bearing mice after two-weeks of CpG-Stat3 siRNA treatment (as in Fig. 2 ) compared to untreated control. The immunostimulatory but non-silencing CpG-Luciferase siRNA increased effector T cell numbers only slightly. Correspondingly, CpG-Stat3 siRNA and not CpG-Luciferase siRNA injections triggered CD8 + T cell activation as indicated by the CD69 upregulation (Fig. 6B) . The generation of adaptive anti-cancer immune responses is known to correlate with the increased ratio of effector to regulatory T cells within the tumor 32 . Thus, we evaluated the numbers of CD4 + FoxP3 + Treg cells in mice treated for two weeks using CpG-siRNA as described above. Even though percentage of total CD4 + T cells did not significantly change ( Supplementary Fig. 5B ), we observed an average ~50% reduction in splenic Tregs (CD4 + /FoxP3 + ) in AML-bearing mice after treatment using Stat3
targeting CpG-siRNA and not control conjugate compared to negative control (Fig. 6C) . Altogether, these findings indicate that systemic CpG-Stat3 siRNA treatment improves the ratio of effector CD8 + T cells to Tregs thereby generating potent adaptive antitumor immunity in mice with disseminated leukemia.
Anti-leukemic effects of CpG-Stat3 siRNA depend on CD8 + T cell-mediated adaptive immunity
Based on the above results CD8 + T cells are likely implicated in anti-leukemic effects of targeted STAT3-inhibition/TLR9-activation. To corroborate these findings, we depleted CD8 + cells using specific antibodies in AML-bearing mice and then followed with 6 repeated injections of CpG-Stat3
siRNA. The anti-leukemic potential of CpG-Stat3 siRNA was reduced by ~80% in CD8 + T celldepleted mice compared to controls, proving that effector T cells play key role in AML regression (Fig.   7A ). We further assessed whether CD8 + T cell activation following in vivo CpG-Stat3 siRNA treatment is tumor antigen-specific. First, we used the irradiated CMM + AML cells as a source of polyvalent tumor antigens for activation of splenic T cells isolated from CpG-siRNA-treated mice. ELISPOT assay detected significantly increased production of IFNγ in splenocytes derived from CpG-Stat3 siRNA-treated mice compared to untreated or control treated mice (Fig. 7B) STAT3 gained recognition as a promising therapeutic target in AML for its oncogenic role in tumor cell proliferation and survival 8, 9 . It was also demonstrated that while driving AML cell proliferation STAT3 suppresses differentiation of leukemic cells 33 . This is similar to the function of shown to directly control PD-L1 expression in T cell lymphoma and later also in IL-6-induced tolerogenic APCs 45, 46 . In our study, the increased STAT3 activity in AML cells correlated with elevated plasma levels of IL-6, which is known as a hallmark of cancer-induced inflammations and a major 47 . High plasma levels of IL-6 are an unfavorable prognostic factor for AML patients' survival 48 . Therefore, targeting STAT3 by CpG-siRNA approach likely interrupts the tolerogenic feedforward loop, reducing both STAT3 activation and IL-6 production.
In addition to tolerogenic AML cells and dysfunctional DCs, regulatory T cell have important role in promoting immune tolerance in leukemia 4 . We demonstrate that systemic CpG-Stat3 siRNA treatment reduces Treg numbers, while increasing recruitment of activated CD8 T cells into major leukemia reservoirs, such as spleen and bone marrow. Increased ratio of tumor-infiltrating effector CD8 T cells to Tregs is an indicator of successful cancer immunotherapy correlated to tumor rejection 32, 49 . This is likely an indirect effect of CpG-Stat3 siRNA-mediated induction of tumor-antigen specific responses, as confirmed in two independent AML models in vivo using peptide antigen and whole irradiated tumor cells. Thus, our approach supports generation of polyvalent and multifaceted immune responses that are more likely to eliminate AML cells together with LSCs, which show selective expression of many leukemia-specific antigens 1 .
Our findings imply that systemic administration of naked CpG-siRNA conjugates avoided major pitfalls in application of TLR agonists as immunoadjuvants, namely desensitization/tolerization of immune cells after repeated TLR stimulation 17 . This is likely an effect of TLR9 triggering liberated from the negative effect of potentially tolerogenic STAT3 signaling 15 . At the same time, we did not observe autoimmune effects of long-term, over two-month CpG-Stat3 siRNA treatment. Due to its role for stem cell renewal, the potential risk of systemic STAT3 inhibition could be deregulation of hematopoiesis 12 . However, as verified in our control experiments CpG-Stat3 siRNA conjugates were not internalized by mouse hematopoietic stem cells and did not significantly affect leukocytes in tumor-free mice ( Supplementary Fig. 7) . Therefore, the myeloid cell-specific CpG-Stat3 siRNA strategy seems to overcome major challenges faced by pharmacologic inhibitors aimed at this In vivo pre-treated splenic AML cells were co-cultured in vitro with autologous T cell at 1:1 for 3 days.
T cell proliferation was assessed using CFSE dilution assay. Shown are results representative for 3 independent experiments. 
